GHK-Cu

Overview

GHK-Cu is the copper(II) complex of the small human peptide glycyl-L-histidyl-L-lysine (GHK), a chain of just three amino acids (glycine, L-histidine, L-lysine). Unlike many compounds discussed on this site, GHK is naturally present in the human body: it is found in plasma, saliva, and urine, and is thought to be released locally when tissue is injured. In cosmetic ingredient labeling it appears under the INCI name Copper tripeptide-1.

A frequently cited observation is that circulating GHK declines with age. Review literature reports plasma GHK of roughly 200 ng/mL at age 20, falling to about 80 ng/mL by age 60 (Pickart et al., 2015). Because GHK has measurable activity in laboratory models of skin and tissue repair, this age-related decline is often offered as part of the rationale for using it as a topical cosmetic ingredient.

The compound has a genuinely well-documented body of laboratory research on wound healing, collagen and extracellular-matrix synthesis, antioxidant defense, and gene-expression modulation. The critical distinction for readers is between its two very different real-world uses: a long-established topical cosmetic ingredient (with some supportive human skin studies and a formal cosmetic safety review) versus an injectable "research" peptide (which has essentially no human clinical trial evidence). This entry keeps those two contexts separate throughout.

Chemistry and structure

GHK is a tripeptide; GHK-Cu is that peptide chelating one copper(II) ion.

The copper(II) ion is coordinated by the imidazole nitrogen of histidine, the alpha-amino group of glycine, and a deprotonated amide nitrogen of the glycine–histidine peptide bond, with the lysine side chain remaining free. A chemically important point is that the redox activity of copper is "silenced" when it is bound in this complex: free copper ions can catalyze damaging oxidative reactions, but the GHK-bound form is described as delivering copper into cells in a comparatively non-toxic state (Pickart et al., 2012).

Mechanism of action

Proposed mechanisms come from a large body of in vitro and animal work, much of it from a small number of research groups. The most frequently described actions are:

• Copper transport and homeostasis. The defining feature of GHK is its high-affinity copper binding, which is thought to shuttle copper into and out of cells in a controlled, low-toxicity form, supporting copper-dependent enzymes such as superoxide dismutase (Pickart et al., 2012).
• Collagen and extracellular-matrix synthesis. In fibroblast cultures, GHK has been reported to stimulate synthesis of collagen, elastin, and glycosaminoglycans, and to modulate matrix metalloproteinases and their inhibitors (TIMP-1, TIMP-2), influencing tissue remodeling (Pickart et al., 2015).
• Wound healing and angiogenesis. Animal and cell models describe increased expression of growth factors, promotion of blood-vessel formation, and faster re-epithelialization (Pickart & Margolina, 2018).
• Antioxidant and anti-inflammatory effects. GHK is described as quenching toxic products of lipid peroxidation (such as 4-hydroxynonenal and acrolein) and as suppressing pro-inflammatory signaling, including NF-κB (Dou et al., 2020).
• Gene-expression modulation. Microarray analyses have reported that GHK can up- or down-regulate large numbers of human genes (figures of several thousand are cited), including genes involved in DNA repair and tissue regeneration (Pickart & Margolina, 2018).

These overlapping actions (tissue repair, alongside the antioxidant defense and angiogenesis seen with peptides studied for tissue repair such as BPC-157) are why GHK-Cu is often described as "regenerative." That label is best understood as a summary of laboratory findings, not a proven clinical outcome in people.

Research and evidence

The evidence for GHK-Cu is genuinely mixed: there is solid mechanistic and laboratory support, a modest amount of human cosmetic data, and some human studies that were negative or inconclusive. The table labels evidence type explicitly.

Topical cosmetic — human studies

The strongest human-relevant data concern topical application to skin. Several small placebo-controlled facial studies (typically ~12 weeks, in women around age 50) have reported improvements such as firmer skin, reduced fine lines, and increased skin density and thickness, with some histological evidence of keratinocyte proliferation (reviewed in Pickart et al., 2015). These studies are generally small, industry-associated, and not always rigorously controlled, so they support cosmetic plausibility rather than proving a strong, consistent effect.

Human results are not uniformly positive. A controlled study of GHK-Cu skincare applied to CO2 laser–resurfaced skin found no statistically significant objective improvement in erythema resolution, wrinkles, or overall skin quality versus control, although patient satisfaction was higher in the GHK-Cu group (Miller et al., 2006). This is an important counterweight to marketing claims.

Wound healing — in vitro and animal evidence

In fibroblast cultures and in several animal wound models, GHK-Cu has been reported to accelerate wound closure, improve collagen remodeling, and enhance angiogenesis (Adnan et al., 2025). However, the same body of literature includes a negative result: a controlled study in an irradiated rat flap model found no difference in flap ischemia, blood-vessel number, or VEGF expression between topical GHK-Cu and control (Parker et al., 2013). The wound-healing evidence is therefore promising in some models but not uniform, and it is predominantly preclinical.

Injectable / systemic use — no human evidence

GHK-Cu is also sold as an injectable "research peptide." There are no published human clinical trials evaluating injected GHK-Cu for any indication. The favorable laboratory and topical findings do not transfer to systemic injection, and the short plasma half-life of tripeptides (reported as roughly under 30 minutes, with rapid excretion) further complicates assumptions about systemic activity (Adnan et al., 2025).

Safety and risks

Safety information differs sharply between the topical and injectable contexts.

• Topical use, generally well tolerated. The U.S. Cosmetic Ingredient Review (CIR) Expert Panel assessed Copper tripeptide-1 (and related peptides) and concluded they are safe in cosmetics in the present practices of use and concentration, citing low use levels and negative irritation, sensitization, and genotoxicity findings (Johnson et al., 2018). Reported topical adverse effects are uncommon and generally mild (such as irritation or sensitivity), more likely at higher concentrations.
• Copper-overload caution (theoretical). Because the molecule delivers copper, a theoretical concern is copper accumulation. In practice, the amount of copper delivered by normal topical cosmetic use is very small and is not considered a systemic toxicity risk in the cosmetic safety literature. People with disorders of copper metabolism, for example Wilson disease, represent a population where any copper-delivering product warrants extra caution, and such concerns are most relevant to non-topical exposure rather than ordinary cosmetic use.
• Injectable use, unknown safety. The systemic safety of injected GHK-Cu in humans is not established. There are no controlled human safety data, no pharmacovigilance system, and the additional risks of unregulated injectable products (contamination, mislabeling, incorrect concentration) apply.

Regulatory and cosmetic status

GHK-Cu occupies an unusual position: it is a well-accepted cosmetic ingredient but not an approved medicine.

• Cosmetics (topical). Under the INCI name Copper tripeptide-1, GHK-Cu is a widely used cosmetic ingredient in skin and hair products. In the United States it falls under cosmetic regulation, and the independent CIR panel has reviewed it as safe as used (Johnson et al., 2018). In the EU, copper peptides are permitted in cosmetics, with each finished product requiring its own safety assessment.
• Medicines. GHK-Cu is not approved as a drug by the FDA, EMA, or other major regulators for any therapeutic (non-cosmetic) indication. It is not a recognized injectable medicine.
• Research / injectable material. Injectable GHK-Cu is sold as a research chemical, commonly labeled "for research use only, not for human consumption."

How it compares

GHK-Cu is best understood by separating its two contexts and by contrasting it with other peptides discussed in a tissue-repair framing. The comparison below is descriptive, not a ranking or endorsement.

The honest summary: GHK-Cu has real, citable evidence as a topical cosmetic ingredient and a genuine laboratory mechanism, but its injectable/systemic use rests on no human trials, the same evidence gap that affects other repair-marketed peptides such as BPC-157.

Common misconceptions

• "GHK-Cu is a synthetic drug." GHK is a naturally occurring human peptide; GHK-Cu is its copper complex. It can be made synthetically for formulation, but the molecule itself is not foreign to the body.
• "It's clinically proven to reverse aging." Topical cosmetic studies are small and mixed, and at least one controlled human study (post-laser skin) found no objective benefit. The "regenerative" and "thousands of genes" language describes laboratory findings, not proven clinical outcomes.
• "Topical safety means injection is safe." The favorable cosmetic safety review applies to topical use at low concentrations. Injectable GHK-Cu has no human trial evidence and unknown systemic safety.
• "More copper peptide is always better." Activity in cell models is concentration-dependent, and excessive concentrations raise cytotoxicity and irritation concerns; cosmetic use levels are deliberately low.
• "GHK-Cu and tissue-repair injectables are interchangeable." GHK-Cu is a distinct molecule with its own chemistry and evidence base; it should not be conflated with other peptides studied for repair, such as BPC-157.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources. The creator is treated as a knowledgeable enthusiast, not peer review; each statement below was verified or corrected against the primary literature.

Verified additions

• The molecule's origin is a real 1973 discovery. GHK was first isolated from human serum by Loren Pickart, who found that serum from younger donors kept cultured liver cells alive better than serum from older donors and traced the effect to this tripeptide [In vitro] (Pickart & Thaler, Nature New Biology 1973). This is the primary source behind the widely repeated "young blood heals better" story.
• There is one genuine human wound-healing trial — and it is topical. A multicentre, randomised, evaluator-blinded, placebo-controlled study of topical GHK-Cu gel (Iamin) in diabetic neuropathic foot ulcers reported significantly greater wound closure than vehicle (median area closure 98.5% vs 60.8%) [Human] (Mulder et al., Wound Repair and Regeneration 1994). This is stronger human evidence than cosmetic-only data, but it is topical, not injected.
• The "thousands of genes" figure traces to a computational analysis, not a clinical outcome. GHK's reported modulation of more than 4,000 human genes and the "resetting genes toward a healthy state" language come from gene-expression / Connectivity-Map analyses of cultured cells (cancer and COPD lines) [In vitro] (Pickart, Vasquez-Soltero & Margolina, BioMed Research International 2014) — a real and interesting laboratory signature, not proof of reversed aging in people.

Claims that don't hold up

• "It should be injected into everyone over 30 — it's a systemic drug, not a skin peptide." Every piece of real human GHK-Cu data is topical (the cosmetic studies and the Mulder 1994 ulcer trial). There are no published human trials of injected GHK-Cu for any indication, so the leap from topical/lab findings to systemic injection is unsupported.
• "It raises ATP by 67% and delivers copper straight to your mitochondria." The 67% figure and the "mitochondria-targeting" studies do not resolve to any identifiable primary paper. Copper is genuinely required by cytochrome-c-oxidase (complex IV), but that a GHK-Cu dose measurably boosts human ATP by a specific percentage is [Hypothesis], not a demonstrated result.
• "A 2007 study showed it blocks 5-alpha-reductase 80% and grows hair follicles 67%." Misattribution. The real Pyo et al. 2007 study was of AHK-Cu (alanyl-histidyl-lysine copper), a different peptide, tested ex vivo / in vitro; it reported follicle elongation and dermal-papilla proliferation with raised VEGF and lowered TGF-β1 — not an 80% 5-alpha-reductase block or a 67% follicle-size gain, and not GHK-Cu [In vitro] (Pyo et al., Archives of Pharmacal Research 2007).
• "Diabetic foot ulcers: 88% healed vs 34%, 6.2 vs 11.4 weeks." No published trial reports those numbers. The real human topical trial (Mulder 1994) reported 98.5% vs 60.8% median area closure — different figures, and topical rather than injected. The quoted percentages and healing times appear fabricated or garbled.
• "Proven safe in 70+ clinical studies." The large body of GHK-Cu research is overwhelmingly in vitro, animal, or topical-cosmetic; it does not include controlled human safety trials of injectable use. "70+ clinical studies" overstates the human safety evidence, which for injection is essentially absent.
• "It regenerates brain, kidney and heart tissue in people — NGF +300%, stroke damage −55%, kidney fibrosis −65%, insulin sensitivity +34%." These precise human-outcome percentages do not trace to primary human trials; the underlying neuro-, renal- and metabolic-repair signals are at best [Animal] or [In vitro]. Presenting them as established human results overstates the evidence.